A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

In-house counsel must shift from being perceived as the “Department of No” to a trusted strategic advisor. That is the most significant message that Bindu Cudjoe and Judith McKay delivered in a ...

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Abstract: The performance of medical image classification has been enhanced by deep convolutional neural networks (CNNs), which are typically trained with cross-entropy (CE) loss. However, when the ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

In a 72-week clinical trial, tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy), with ...